Cracking The Code: Understanding Analyst Reviews For Kymera Therapeutics
Cracking The Code: Understanding Analyst Reviews For Kymera Therapeutics
破译代码：了解kymera therapeutics的分析师评论
Ratings for Kymera Therapeutics (NASDAQ:KYMR) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
在过去三个月中，有5位分析师为kymera therapeutics (纳斯达克:KYMR) 提供了评级，呈现出看好和看淡的观点混合。
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
总结他们最近的评估，下表展示了过去30天内不断变化的情绪，并将其与之前的几个月进行了比较。
In the assessment of 12-month price targets, analysts unveil insights for Kymera Therapeutics, presenting an average target of $48.6, a high estimate of $53.00, and a low estimate of $46.00. Witnessing a positive shift, the current average has risen by 1.78% from the previous average price target of $47.75.
在对12个月价格目标的评估中，分析师为kymera therapeutics揭示了深入的见解，提出了平均目标价为48.6美元，最高估价为53.00美元，最低估价为46.00美元。现在的平均值较之前的平均目标价格47.75美元上升了1.78%，显示出了积极的走势。
Investigating Analyst Ratings: An Elaborate Study
分析师评级的调查：一项详尽的研究
In examining recent analyst actions...
通过审查近...
登录免费看全文
登录/注册